MRNA Moderna
- 124.025
- +2.135+1.75%
Moderna News
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Deutsche Bank Raises Moderna's Price Target to $85 From $70
Moderna (MRNA) has an average rating of outperform and price targets ranging from $60 to $310, according to analysts polled by Capital IQ. Price: 124.37, Change: +2.48, Percent Change: +2.03
Novo Nordisk, Flagship to Develop Next-generation Obesity Drugs
Moderna's Promise of MRNA Undercut by New RSV Vaccine
Novo Nordisk (NVO.US) invests $600 million to join Metaphor Biotech to build a new chapter in obesity treatment
Novo Nordisk (NVO.US), the manufacturer of popular drugs Ozempic and Wegovy, announced a new research agreement with biotech company Metaphor Biotechnology. The partnership was supported by Flagship Pioneering, which is also the venture capital company behind US vaccine manufacturer Moderna (MRNA.US). Under the agreement, Novo Nordisk agreed to pay up to $600 million to develop the next generation of obesity treatments.
If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today
Novo Nordisk Sets Sights on a Long-Lasting Successor to Its Weight Loss Blockbuster -- Barrons.com
By Josh Nathan-Kazis Novo Nordisk has ridden the monster wave of enthusiasm over Wegovy, its once-weekly obesity shot, to become Europe's most valuable company. Now, it says it is beginning work on a
Moderna's MRNA Dreams Meet Reality With First Post-Covid Shot
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Tesla CEO Elon Musk does not seem to agree with Republicans at least on one thing. On Wednesday, the billionaire, true to his credentials as a tech pioneer, unequivocally backed the mRNA technology, w
Form 144 | Moderna(MRNA.US) Director Proposes to Sell 1.82 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 8, $Moderna(MRNA.US)$ Director NOUBAR B AFEYAN intends to sell 15,000 shares of its common stock on May 8, with a total market value of approximately $1.82 million. NOUBA
AstraZeneca (AZN.US) withdraws COVID-19 vaccine from the market, emphasizing insufficient demand rather than safety factors
The Zhitong Finance App learned that British pharmaceutical giant AstraZeneca (AZN.US) removed its COVID-19 vaccine from the market, which was once popular all over the world, mainly because the market's demand for this vaccine was insufficient, and initially people hoped that it would play a key role in protecting the world from the virus. AstraZeneca said in a statement that at the company's request, the marketing license for the vaccine Vaxzevria in the EU was withdrawn this week because the vaccine is no longer being produced or supplied. The company said the decision was unrelated to any security reasons. AstraZeneca's COVID-19 vaccine and the University of Oxford
AstraZeneca Is Withdrawing COVID Shot Worldwide Due to Vaccine Glut
Check Out What Whales Are Doing With MRNA
Deep-pocketed investors have adopted a bullish approach towards Moderna (NASDAQ:MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled t
Moderna Is Maintained at Buy by UBS
Moderna Is Maintained at Buy by UBS
UBS Maintains Buy on Moderna, Raises Price Target to $151
UBS analyst Eliana Merle maintains Moderna (NASDAQ:MRNA) with a Buy and raises the price target from $143 to $151.
UBS Adjusts Moderna Price Target to $151 From $143, Maintains Buy Rating
Moderna (MRNA) has an average rating of outperform and price targets ranging from $60 to $310, according to analysts polled by Capital IQ. Price: 119.98, Change: -2.15, Percent Change: -1.76
Drug Stock Earnings Recap: Moderna, BHC, and Regeneron
Moderna's Options Frenzy: What You Need to Know
Deep-pocketed investors have adopted a bullish approach towards Moderna (NASDAQ:MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled t
Oppenheimer raised Moderna's price target to $163
Gronghui, May 6 | Oppenheimer: Raise Moderna's target price from $142 to $163 to maintain the “outperforming market” rating.
Moderna Insider Sold Shares Worth $1,663,855, According to a Recent SEC Filing
Noubar Afeyan, Director, on May 01, 2024, sold 15,000 shares in Moderna (MRNA) for $1,663,855. Following the Form 4 filing with the SEC, Afeyan has control over a total of 11,692,969 shares of the com
Analysis
Price Target
No Data
